Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market
SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the companyâs ...
What is the projected impact on Regen BioPharmaâs earnings guidance once HemaXellerate progresses to laterâstage trials?
Are there any intellectual property or patent considerations that could affect the therapyâs commercial exclusivity?
What are the key clinical endpoints for the expanded oncology applications and the probability of meeting them?
10 days ago